Milan, Italy - November 14, 2017 - Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN), a biopharmaceutical company focused on the development of novel therapies for patients
- Advisory Board Characterizes Illness and Treatment Patterns
- Rett Congress Reviews Multi-Organ Impact of Single Symptoms
Milan, Italy & Morristown, N.J. – November 7, 2017
- Continued advancement of the International Burden of Disease in Rett Syndrome Study
- Oral presentation on findings from concept elicitation interviews with caregivers and
Milan, Italy & Morristown, N.J. – October 6, 2017 - Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN), a biopharmaceutical company focused on the development of novel
Not for release, publication or distribution, directly or indirectly, in the United States of America, Canada, Japan or Australia
THIS IS A RESTRICTED COMMUNICATION AND YOU
Not for release, publication or distribution, directly or indirectly, in the United States of America, Canada, Japan or Australia
THIS IS A RESTRICTED COMMUNICATION AND YOU MUST
Not for release, publication or distribution, directly or indirectly, in the United States of America, Canada, Japan or Australia
THIS IS A RESTRICTED COMMUNICATION AND YOU MUST
Not for release, publication or distribution, directly or indirectly, in the United States of America, Canada, Japan or Australia
THIS IS A RESTRICTED COMMUNICATION AND YOU MUST
Milan, Italy – September 14, 2017 – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN), a biopharmaceutical company focused on the development of novel therapies for patients
The information on the following pages may be made available in the United States. By clicking on the link below, you agree that you are in the United States.